{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:38:40Z","timestamp":1762324720815,"version":"3.37.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Basilea Pharmaceutica International Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>EUCAST recently revised the definition of the \u2018I\u2019 category from \u2018intermediate\u2019 to \u2018susceptible, increased exposure\u2019. Consequently, all current antifungal breakpoints have been reviewed and revised breakpoints (v 10.0) have been released.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We investigated isavuconazole and comparator MICs (mg\/L) against contemporary moulds and the consequences of the breakpoint revision for susceptibility classification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Six hundred and ninety-six Aspergillus and 46 other moulds were included. EUCAST E.Def 10.1 azole resistance screening was performed for Aspergillus fumigatus and E.Def 9.3.1 testing of non-susceptible A. fumigatus and other moulds. Most non-wildtype\/resistant isolates underwent cyp51A sequencing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Isavuconazole MIC50\/MIC90s were \u22641\/\u22642\u2009mg\/L for Aspergillus flavus, A. fumigatus and Aspergillus nidulans versus 2\/4\u2009mg\/L for Aspergillus niger and 2\/16\u2009mg\/L for Aspergillus terreus. For the remaining moulds, MICs were highest for Fusarium (16 to &amp;gt;16\u2009mg\/L), lowest for dermatophytes (0.06\u20130.5\u2009mg\/L) and in between for Mucorales and others (1 to &amp;gt;16\u2009mg\/L). A very strong isavuconazole\u2013voriconazole MIC correlation was found for A. fumigatus (Pearson r\u2009=\u20090.888) and itraconazole\u2013posaconazole correlation for A. fumigatus (r\u2009=\u20090.905) and A. terreus (r\u2009=\u20090.848). For A. fumigatus, the revised breakpoints lowered isavuconazole resistance (22.6% to 7.7%, P\u2009&amp;lt;\u20090.0001) and increased voriconazole resistance (3.8% to 6.7%, P\u2009=\u20090.025), resulting in similar resistance rates across the four azoles (range: 6.7%\u20137.7%). For A. terreus, isavuconazole resistance remained unchanged (81.3%) and higher than itraconazole (43.8%, P\u2009=\u20090.004) and posaconazole (53.1%, P\u2009=\u20090.03) resistance. Azole cross-resistance was found in 24\/24, 13\/20 and 4\/90 isolates, and Cyp51A alterations in 16\/18, 1\/7 and 2\/4 sequenced isolates with isavuconazole MICs of &amp;gt;4, 4 and 2\u2009mg\/L, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Isavuconazole displays broad anti-mould activity. The revised breakpoints result in fewer misclassifications of wildtype isolates without compromising detection of resistant mutants.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa212","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T11:28:40Z","timestamp":1589282920000},"page":"2573-2581","source":"Crossref","is-referenced-by-count":5,"title":["Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators"],"prefix":"10.1093","volume":"75","author":[{"given":"Karin Meinike","family":"J\u00f8rgensen","sequence":"first","affiliation":[{"name":"Unit for Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7901-8355","authenticated-orcid":false,"given":"Jesus","family":"Guinea","sequence":"additional","affiliation":[{"name":"Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"CIBER Enfermedades Respiratorias-CIBERES (CB06\/06\/0058), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-1509","authenticated-orcid":false,"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-023X","authenticated-orcid":false,"given":"Rasmus Kr\u00f8ger","family":"Hare","sequence":"additional","affiliation":[{"name":"Unit for Mycology, Statens Serum Institut, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-0144","authenticated-orcid":false,"given":"Maiken Cavling","family":"Arendrup","sequence":"additional","affiliation":[{"name":"Unit for Mycology, Statens Serum Institut, Copenhagen, Denmark"},{"name":"Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"2020082404582728700_dkaa212-B1","doi-asserted-by":"crossref","first-page":"571.e1","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2020082404582728700_dkaa212-B2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/jac\/dkx354","article-title":"Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs","volume":"73","author":"Buil","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020082404582728700_dkaa212-B3","doi-asserted-by":"crossref","first-page":"e00073","DOI":"10.1128\/AAC.00073-19","article-title":"EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates","volume":"63","author":"J\u00f8rgensen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404582728700_dkaa212-B4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cmi.2017.03.023","article-title":"Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates","volume":"23","author":"Astvad","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2020082404582728700_dkaa212-B5","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404582728700_dkaa212-B6","doi-asserted-by":"crossref","first-page":"e00865","DOI":"10.1128\/AAC.00865-19","article-title":"Molecular identification, antifungal susceptibility testing, and mechanisms of azole resistance in Aspergillus species received within a surveillance program on antifungal resistance in Spain","volume":"63","author":"Rivero-Menendez","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404582728700_dkaa212-B7","doi-asserted-by":"crossref","first-page":"E248","DOI":"10.1111\/j.1469-0691.2012.03890.x","article-title":"EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole","volume":"18","author":"Arendrup","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020082404582728700_dkaa212-B8","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1073\/pnas.1117018109","article-title":"Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for fungi","volume":"109","author":"Schoch","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020082404582728700_dkaa212-B9","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1128\/JCM.00989-10","article-title":"Internet-accessible DNA sequence database for identifying fusaria from human and animal infections","volume":"48","author":"O\u2019Donnell","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2020082404582728700_dkaa212-B10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1128\/AEM.61.4.1323-1330.1995","article-title":"Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes","volume":"61","author":"Glass","year":"1995","journal-title":"Appl Environ Microbiol"},{"key":"2020082404582728700_dkaa212-B11","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1128\/JCM.00213-11","article-title":"Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance","volume":"49","author":"Mortensen","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020082404582728700_dkaa212-B12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.drup.2014.01.001","article-title":"Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp","volume":"16","author":"Arendrup","year":"2013","journal-title":"Drug Resist Updat"},{"key":"2020082404582728700_dkaa212-B13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fmicb.2018.00516","article-title":"Azole-resistance in Aspergillus terreus and related species: an emerging problem or a rare phenomenon?","volume":"9","author":"Zoran","year":"2018","journal-title":"Front Microbiol"},{"key":"2020082404582728700_dkaa212-B14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10096-013-1924-7","article-title":"Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment","volume":"32","author":"Guarro","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020082404582728700_dkaa212-B15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/jac\/dkx527","article-title":"Epidemiology of invasive aspergillosis and triazole-resistant Aspergillus fumigatus in patients with haematological malignancies: a single-centre retrospective cohort study","volume":"73","author":"Lestrade","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020082404582728700_dkaa212-B16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3201\/eid2201.151308","article-title":"Azole resistance of Aspergillus fumigatus in immunocompromised patients with invasive aspergillosis","volume":"22","author":"van der Linden","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2020082404582728700_dkaa212-B17","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020082404582728700_dkaa212-B18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2217\/fmb.11.118","article-title":"Azole resistance in Aspergillus: a growing public health menace","volume":"6","author":"Denning","year":"2011","journal-title":"Future Microbiol"},{"key":"2020082404582728700_dkaa212-B19","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404582728700_dkaa212-B20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1128\/AAC.48.2.568-574.2004","article-title":"Three-dimensional models of wild-type and mutated forms of cytochrome P450 14\u03b1-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding","volume":"48","author":"Xiao","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082404582728700_dkaa212-B21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.fgb.2011.08.002","article-title":"The structure\u2013function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance","volume":"48","author":"Snelders","year":"2011","journal-title":"Fungal Genet Biol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2573\/33665227\/dkaa212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/9\/2573\/33665227\/dkaa212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T08:59:49Z","timestamp":1598259589000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/9\/2573\/5859010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,17]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa212","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,17]]}}}